Get started
Author

Junfang Yang

Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
2020 · Xian Zhang, Xin-an Lu, et al. · Blood Advances · 223
PDF
Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
2020 · Xiangyu Zhao, Junfang Yang, et al. · Molecular Therapy — Oncolytics · 135
PDF
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
2022 · Junfang Yang, Jiaping He, et al. · Blood Cancer Journal · 124
PDF
Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia
2021 · Yan-Li Zhao, De-Yan Liu, et al. · Frontiers in Immunology · 76
PDF
Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with CD7 ‐targeted chimeric antigen receptor‐T cell therapy
2023 · Xian Zhang, Junfang Yang, et al. · American Journal of Hematology · 66
A drug-mediated organic electrochemical transistor for robustly reusable biosensors
2024 · Ziling Jiang, Dekai Ye, et al. · Nature Materials · 65
Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
2021 · Jin-Yuan Ho, Lin Wang, et al. · Molecular Therapy — Methods & Clinical Development · 61
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
2021 · Xian Zhang, Junfang Yang, et al. · Cancer Immunology Immunotherapy · 60
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia
2024 · Peihua Lu, Xian Zhang, et al. · Blood · 57
Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies
2019 · Yu Zhao, Zhongfeng Liu, et al. · Clinical Cancer Research · 49
A novel adoptive synthetic TCR and antigen receptor ( STAR ) T‐Cell therapy for B‐Cell acute lymphoblastic leukemia
2022 · Jiasheng Wang, Xian Zhang, et al. · American Journal of Hematology · 47
PDF
Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
2020 · Yu-Hong Chen, Xian Zhang, et al. · Cytotherapy · 43
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
2022 · Xiaoyan Qu, Gang An, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
Ring and Gellhorn pessaries used in patients with pelvic organ prolapse: a retrospective study of 8 years
2018 · Junfang Yang, Jinsong Han, et al. · Archives of Gynecology and Obstetrics · 29
PDF
Diversity at Eight Polymorphic Alu Insertion Loci in Chinese Populations Shows Evidence for European Admixture in an Ethnic Minority Population from Northwest China
2002 · Feng-Xia Xiao, Jun-Fang Yang, et al. · Human Biology · 28
A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia
2018 · Junfang Yang, Jianqiang Li, et al. · Blood · 27
Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia
2019 · Junfang Yang, Pengfei Jiang, et al. · Blood · 26
An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
2020 · Gang An, Weiwei Sui, et al. · Blood · 22
A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia
2019 · Junfang Yang, Jiaping He, et al. · Blood · 22
Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
2023 · Xing-yu Cao, Jian-ping Zhang, et al. · Frontiers in Immunology · 20
A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma
2022 · Xian Zhang, Yali Zhou, et al. · Blood · 18
Pediatric TTMV::RARA‐positive relapsed acute promyelocytie leukemia responsive to venetoclax and achieving long remission after allogenic transplantation
2023 · Jiaqi Chen, Xiaosu Zhou, et al. · Pediatric Blood & Cancer · 17
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
2018 · Peihua Lu, Xin-an Lu, et al. · Journal of Clinical Oncology · 17
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy
2024 · Xing‐yu Cao, Jian‐ping Zhang, et al. · British Journal of Haematology · 16
PDF
Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)
2020 · Junfang Yang, Pengfei Jiang, et al. · Blood · 16
Works count: 95
Citation count: 1,553
H-index: 20
I10-index: 34
Year
Topic
Type